Journal questions use of cannabis spray drug for MS

LONDON (Reuters) – There is little evidence to back the use of a cannabis extract spray made by GW Pharmaceuticals for spasticity in patients with multiple sclerosis, according to a medical journal review published on Thursday. GW Pharma said the report in the Drug and Therapeutics Bulletin (DTB), a British Medical Journal publication, gave "a misleading view of the drug" and contained a number of errors. Sativex is sold as a prescription drug in Britain by GW's partner, German group Bayer. …